Amygdala-derived-EEG-fMRI-pattern neurofeedback for the treatment of chronic post-traumatic stress disorder. A prospective, multicenter, multinational study evaluating clinical efficacy.

​

/ Fruchter E,  Goldenthal N,  Adler LA,  Gross R,  Harel EV, Deutsch L,  Nacasch N,  Grinapol  S,  Amital D,  Voigt JD,  Marmar CR.
Psychiatry Research, Volume 333, 2024.  

 

A prospective, single arm, multisite, multinational, open label trial assessing the safety and efficacy of Amygdala-derived EFP neurofeedback treatment for chronic PTSD. Participants, including veterans and civilians, underwent 15 neurofeedback sessions over 8 weeks and; baseline, termination (8 weeks) and 3 month post treatment assessments with validated measures.

The primary endpoint was met, with a CAPS-5 MCID response rate of 66.7 %. The average reduction in CAPS-5 total scores at 3 month follow up was 13.5 points, more than twice the MCID. Changes from baseline in CAPS-5, PCL-5, PHQ-9 scores at 8 weeks and the 3 month follow-up demonstrated statistically significant improvements in response and; demonstrated effect sizes ranging from 0.46 to 1.07.  Adverse events were mild and resolved after treatment.
 

This study builds on prior research demonstrating similar outcomes using amygdala-derived neurofeedback. Positive attributes of this therapy include monitoring by non-physician personnel, affordability, accessibility, and tolerability.

​

To read the full article on Psychiatry Research - https://www.sciencedirect.com/science/article/pii/S0165178123006613